Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Impact · against what's priced in

Bright Minds Biosciences is a strong buy following positive Phase 2 data for BMB-101 and a clear path toward registrational trials. Zephyr Energy reduces its funding risk through a $15 million letter of intent for the Paradox Project.

DRUG+0.80

No priced-in read yet

In context

Positive Phase 2 results showing a 73.1% reduction in absence seizures and a 63.3% reduction in major motor seizures provide a direct catalyst for valuation and a path to FDA approval.

Read from the article alone

• healthcare
• biotech
• DRUG
• ZPHR
• clinical trials
• drug development
• epilepsy
• pharma
• phase 2

Search tags